

Alicja E Grzegorzewska

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1479253/publications.pdf>

Version: 2024-02-01

84
papers

667
citations

687363

13
h-index

677142

22
g-index

101
all docs

101
docs citations

101
times ranked

711
citing authors

#	ARTICLE	IF	CITATIONS
1	Polymorphism rs368234815 of interferon lambda 4 gene and spontaneous clearance of hepatitis C virus in haemodialysis patients: a case-control study. <i>BMC Infectious Diseases</i> , 2021, 21, 102.	2.9	1
2	Paraoxonase 1 concerning dyslipidaemia, cardiovascular diseases, and mortality in haemodialysis patients. <i>Scientific Reports</i> , 2021, 11, 6773.	3.3	14
3	Interferon- λ 3 Gene Polymorphic Variants, rs4803217 and rs12980275, Responsiveness to HBV Vaccine and Outcome of HBV and HCV Exposure in Hemodialyzed Patients. <i>Hepatitis Monthly</i> , 2021, 21, .	0.2	1
4	Paraoxonase 1 gene (PON1) variants concerning hepatitis C virus (HCV) spontaneous clearance in hemodialysis individuals: a case-control study. <i>BMC Infectious Diseases</i> , 2021, 21, 875.	2.9	0
5	Paraoxonase 1 gene variants concerning cardiovascular mortality in conventional cigarette smokers and non-smokers treated with hemodialysis. <i>Scientific Reports</i> , 2021, 11, 19467.	3.3	2
6	Paraoxonase 1 gene polymorphisms concerning non-insulin-dependent diabetes mellitus nephropathy in hemodialysis patients. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107687.	2.3	5
7	Exposure to hepatitis E virus in hemodialysis patients from west-central Poland. <i>Journal of Medical Virology</i> , 2020, 92, 1363-1368.	5.0	0
8	Polymorphism rs368234815 of interferon- λ 4 gene and generation of antibodies to hepatitis B virus surface antigen in extracorporeal dialysis patients. <i>Expert Review of Vaccines</i> , 2020, 19, 293-303.	4.4	5
9	FP692FOXO3 RS4946936 AND ANGPTL6 RS8112063 ARE PROGNOSTIC FACTORS OF SURVIVAL IN HEMODIALYSIS PATIENTS. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.7	0
10	FP679IFNL4 rs368234815 POLYMORPHISM AND SPONTANEOUS CLEARANCE OF HEPATITIS C VIRUS IN HEMODIALYSIS PATIENTS. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, .	0.7	1
11	Circulating interferon- λ 3 and post-vaccination antibodies against the surface antigen of hepatitis B virus in hemodialysis patients exposed to hepatitis E virus. <i>Cytokine</i> , 2019, 123, 154766.	3.2	1
12	Calcium-sensing receptor gene (CASR) polymorphisms and CASR transcript level concerning dyslipidemia in hemodialysis patients: a cross-sectional study. <i>BMC Nephrology</i> , 2019, 20, 436.	1.8	5
13	Genetic Polymorphisms within Interferon- λ Region and Interferon- λ 3 in the Human Pathophysiology: Their Contribution to Outcome, Treatment, and Prevention of Infections with Hepatotropic Viruses. <i>Current Medicinal Chemistry</i> , 2019, 26, 4832-4851.	2.4	2
14	ENHO, RXRA, and LXRA polymorphisms and dyslipidaemia, related comorbidities and survival in haemodialysis patients. <i>BMC Medical Genetics</i> , 2018, 19, 194.	2.1	8
15	Relative indoleamine 2,3-dioxygenase transcript level concerning anti-HBs titers in response to HBV vaccination in hemodialysis patients. <i>Expert Review of Vaccines</i> , 2018, 17, 947-953.	4.4	1
16	The Calcium-Sensing Receptor Gene Polymorphism rs1801725 and Calcium-Related Phenotypes in Hemodialysis Patients. <i>Kidney and Blood Pressure Research</i> , 2018, 43, 719-734.	2.0	6
17	Correlations of indoleamine 2,3-dioxygenase, interferon- λ 3, and anti-HBs antibodies in hemodialysis patients. <i>Vaccine</i> , 2018, 36, 4454-4461.	3.8	3
18	IFN- λ 4 gene polymorphisms, circulating IFN- λ 3, and clinical variables in hemodialysis patients exposed to hepatitis E virus. <i>Polish Archives of Internal Medicine</i> , 2018, 128, 344-353.	0.4	3

#	ARTICLE	IF	CITATIONS
19	Polymorphisms of T helper cell cytokine-associated genes and survival of hemodialysis patients – a prospective study. <i>BMC Nephrology</i> , 2017, 18, 165.	1.8	3
20	Circulating Interferon- γ , Responsiveness to HBV Vaccination, and HBV/HCV Infections in Haemodialysis Patients. <i>BioMed Research International</i> , 2017, 2017, 1-15.	1.9	6
21	Monocyte Chemotactic Protein-1 (Cytokine, Receptors, and Gene Polymorphisms) in Hepatitis. <i>Biomarkers in Disease</i> , 2017, , 927-955.	0.1	1
22	Titers of antibodies to the surface antigen of hepatitis B virus after vaccination in relation to immunity-related gene variants. A prospective study among hemodialysis patients. <i>Polish Archives of Internal Medicine</i> , 2017, 127, 481-489.	0.4	3
23	Polymorphisms of Vitamin D Signaling Pathway Genes and Calcium-Sensing Receptor Gene in respect to Survival of Hemodialysis Patients: A Prospective Observational Study. <i>International Journal of Endocrinology</i> , 2016, 2016, 1-11.	1.5	6
24	Salusins and adropin: New peptides potentially involved in lipid metabolism and atherosclerosis. <i>Advances in Medical Sciences</i> , 2016, 61, 282-287.	2.1	26
25	Antibodies to hepatitis B virus surface antigen and survival of hemodialysis patients – a prospective study. <i>Expert Review of Vaccines</i> , 2016, 15, 1063-1074.	4.4	7
26	Involvement of adropin and adropin-associated genes in metabolic abnormalities of hemodialysis patients. <i>Life Sciences</i> , 2016, 160, 41-46.	4.3	10
27	Antibodies to HBV surface antigen in relation to interferon- γ in hemodialysis patients. <i>Vaccine</i> , 2016, 34, 4866-4874.	3.8	6
28	Associations of the calcium-sensing receptor gene CASR rs7652589 SNP with nephrolithiasis and secondary hyperparathyroidism in haemodialysis patients. <i>Scientific Reports</i> , 2016, 6, 35188.	3.3	12
29	Self-Reported Physical Activity, Quality of Life, and Psychological Status in Relation to Plasma 25-Hydroxyvitamin D Concentration in Patients Treated with Hemodialysis. <i>Kidney and Blood Pressure Research</i> , 2016, 41, 886-900.	2.0	12
30	Serum cardiac troponin T and effective blood flow in stable extracorporeal dialysis patients. <i>International Urology and Nephrology</i> , 2016, 48, 419-429.	1.4	2
31	Alkaptonuria: a disease with dark brown urine. <i>Polish Archives of Internal Medicine</i> , 2016, 126, 284-5.	0.4	2
32	Monocyte Chemotactic Protein-1 (Cytokine, Receptors, and Gene Polymorphisms) in Hepatitis. <i>Exposure and Health</i> , 2015, , 1-29.	4.9	0
33	Association of Retinoid X Receptor Alpha Gene Polymorphism with Clinical Course of Chronic Glomerulonephritis. <i>Medical Science Monitor</i> , 2015, 21, 3671-3681.	1.1	3
34	Prophylactic vaccinations in chronic kidney disease: Current status. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 2599-2605.	3.3	17
35	Clinical aspects of vitamin D-binding protein gene polymorphisms in hemodialysis patients. <i>Polish Archives of Internal Medicine</i> , 2015, 125, 8-17.	0.4	6
36	Effect of interferon γ gene polymorphisms, rs8099917 and rs12979860, on response to hepatitis B virus vaccination and hepatitis B or C virus infections among hemodialysis patients. <i>Polish Archives of Internal Medicine</i> , 2015, 125, 894-902.	0.4	9

#	ARTICLE	IF	CITATIONS
37	T helper cell-related cytokine gene polymorphisms and vitamin D pathway gene polymorphisms as predictors of survival probability in patients on renal replacement therapy. <i>Polish Archives of Internal Medicine</i> , 2015, 125, 511-520.	0.4	5
38	Single nucleotide polymorphisms of vitamin D binding protein, vitamin D receptor and retinoid X receptor alpha genes and response to hepatitis B vaccination in renal replacement therapy patients. <i>Expert Review of Vaccines</i> , 2014, 13, 1395-1403.	4.4	25
39	Hepatitis B vaccination in chronic kidney disease patients: a call for novel vaccines. <i>Expert Review of Vaccines</i> , 2014, 13, 1317-1326.	4.4	27
40	T-Cell Cytokine Gene Polymorphisms and Vitamin D Pathway Gene Polymorphisms in End-Stage Renal Disease due to Type 2 Diabetes Mellitus Nephropathy: Comparisons with Health Status and Other Main Causes of End-Stage Renal Disease. <i>Journal of Diabetes Research</i> , 2014, 2014, 1-17.	2.3	9
41	Monocyte chemoattractant protein-1 gene (MCP-1-2518 A/G) polymorphism and serological markers of hepatitis B virus infection in hemodialysis patients. <i>Medical Science Monitor</i> , 2014, 20, 1101-1116.	1.1	12
42	Effect of lifestyle changes and atorvastatin administration on dyslipidemia in hemodialysis patients: a prospective study. <i>Polish Archives of Internal Medicine</i> , 2014, 124, 443-451.	0.4	9
43	Association of the interleukin-12 polymorphic variants with the development of antibodies to surface antigen of hepatitis B virus in hemodialysis patients in response to vaccination or infection. <i>Molecular Biology Reports</i> , 2013, 40, 6899-6911.	2.3	19
44	IL4R and IL13 polymorphic variants and development of antibodies to surface antigen of hepatitis B virus in hemodialysis patients in response to HBV vaccination or infection. <i>Vaccine</i> , 2013, 31, 1766-1770.	3.8	10
45	Single Pool Urea Kinetic Modeling. <i>Studies in Computational Intelligence</i> , 2013, , 563-626.	0.9	0
46	Polymorphism of monocyte chemoattractant protein 1 (MCP1 -2518 A/G) and responsiveness to hepatitis B vaccination in hemodialysis patients. <i>Polish Archives of Internal Medicine</i> , 2013, 124, 10-18.	0.4	7
47	Hepatitis B Vaccination in Chronic Kidney Disease: Review of Evidence in Non-Dialyzed Patients. <i>Hepatitis Monthly</i> , 2012, 12, e7359.	0.2	37
48	Interleukin-18 Promoter Polymorphism and Development of Antibodies to Surface Antigen of Hepatitis B Virus in Hemodialysis Patients. <i>Kidney and Blood Pressure Research</i> , 2012, 35, 1-8.	2.0	14
49	Antibodies to hepatitis B virus surface antigen and interleukin 12 and interleukin 18 gene polymorphisms in hemodialysis patients. <i>BMC Nephrology</i> , 2012, 13, 75.	1.8	25
50	Rozsiany miÅ™sak Kaposiego skÅ³ry u pacjentki przyjmujÅ„cej tryptolid/tryptolid z powodu reumatoidalnego zapalenia stawÅ³w. <i>Medical Science Monitor</i> , 2012, 18, CS67-CS71.	1.1	12
51	Seroconversion rate to positivity for antibodies against core antigen of hepatitis B virus and duration of renal replacement therapy. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 970-976.	0.7	12
52	Bone mineral density, its predictors, and outcomes in peritoneal dialysis patients. <i>Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis</i> , 2011, 27, 140-5.	0.1	7
53	Visfatin and endogenous secretory receptor for advanced glycation end-products in diabetic type 2 and non-diabetic patients undergoing intermittent hemodialysis. <i>International Urology and Nephrology</i> , 2010, 42, 441-452.	1.4	2
54	Antibodies to Core Antigen of Hepatitis B Virus in Patients on Renal Replacement Therapy: Association with Demographic, Clinical and Laboratory Data. <i>Nephron Clinical Practice</i> , 2010, 114, c194-c203.	2.3	7

#	ARTICLE	IF	CITATIONS
55	Predictors of bone mineral density in dialyzed and non-dialyzed patients with chronic kidney disease. <i>Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis</i> , 2010, 26, 116-24.	0.1	4
56	Natural killer cells in continuous ambulatory peritoneal dialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 1696-1697.	0.7	1
57	Recurrent atrioventricular nodal re-entrant tachycardia treated with percutaneous ablation in a 75-year old patient undergoing intermittent hemodialysis. <i>International Urology and Nephrology</i> , 2009, 41, 225-230.	1.4	1
58	Biocompatible peritoneal dialysis solutions: do they indeed affect the outcome?. , 2009, 119, 242-7.		1
59	Total body mass is better than body mass index as a prognostic parameter for bone mineral density in dialyzed patients. <i>Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis</i> , 2009, 25, 178-80.	0.1	4
60	Does ingestion of regular coffee influence serum lipid profile in dialysis patients?. <i>Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis</i> , 2009, 25, 181-6.	0.1	2
61	Evaluation of hemodialysis adequacy using online Kt/V and single-pool variable-volume urea Kt/V. <i>International Urology and Nephrology</i> , 2008, 40, 771-778.	1.4	13
62	Coffee consumption and bone mineral density in dialysis patients. <i>Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis</i> , 2008, 24, 84-9.	0.1	1
63	Low molecular weight heparins and antiplatelet drugs, and bone mineral density in dialysis patients. <i>Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis</i> , 2008, 24, 125-31.	0.1	2
64	Nodular pulmonary amyloidosis and Sjogren's syndrome in a patient treated with intermittent haemodialysis (IHD). <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 1485-1486.	0.7	2
65	Nodular pulmonary amyloidosis and Sjogren's syndrome in a patient treated with intermittent hemodialysis. <i>Hemodialysis International</i> , 2007, 11, 406-410.	0.9	4
66	Influence of age and sex on bone mineral density in dialysis patients. <i>Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis</i> , 2007, 23, 77-81.	0.1	3
67	Serum level of intact parathyroid hormone and other markers of bone metabolism in dialyzed patients. <i>Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis</i> , 2007, 23, 162-5.	0.1	1
68	Serum markers of bone turnover in dialyzed patients separated according to age. <i>International Urology and Nephrology</i> , 2006, 38, 311-316.	1.4	6
69	Comparisons of Kt/V evaluated using an online method and calculated from urea measurements in patients on intermittent hemodialysis. <i>Hemodialysis International</i> , 2006, 10, S5-S9.	0.9	26
70	Markers of bone turnover in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 3602-3603.	0.7	0
71	Serum markers of bone turnover in dialyzed patients grouped by level of intact parathyroid hormone. <i>Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis</i> , 2006, 22, 203-6.	0.1	0
72	Total lymphocyte count and subpopulation lymphocyte count in relation to blood bicarbonate concentration in peritoneal dialysis patients. <i>Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis</i> , 2005, 21, 31-4.	0.1	2

#	ARTICLE	IF	CITATIONS
73	Total lymphocyte count and subpopulation lymphocyte counts in relation to dietary intake and nutritional status of peritoneal dialysis patients. <i>Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis</i> , 2005, 21, 35-40.	0.1	12
74	Using the ratio of serum osteoprotegerin ligand to osteoprotegerin to evaluate renal osteodystrophy in dialysis patients. <i>Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis</i> , 2005, 21, 188-93.	0.1	3
75	Peritoneal dialysis with solutions low in glucose degradation products is associated with improved biocompatibility profile towards peritoneal mesothelial cells. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 917-924.	0.7	66
76	Serum levels of cancer antigen 125 and interleukin-15 in relation to the nutrition status of peritoneal dialysis patients. <i>Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis</i> , 2004, 20, 185-9.	0.1	4
77	Total and subset lymphocyte counts, angiotensin converting enzyme inhibitors, and dialysis duration in younger and older peritoneal dialysis patients. <i>Advances in Peritoneal Dialysis Conference on Peritoneal Dialysis</i> , 2004, 20, 190-3.	0.1	2
78	Lymphocyte Subset Counts in CAPD Patients in Relation to Administration of Recombinant Human Erythropoietin and Angiotensin-Converting Enzyme Inhibitors. <i>Peritoneal Dialysis International</i> , 2002, 22, 625-628.	2.3	4
79	Possible factors contributing to similar peritoneal dialysis outcome in patients over 60 years of age and the younger ones. <i>International Urology and Nephrology</i> , 2002, 34, 565-572.	1.4	3
80	Lymphocyte subset counts in CAPD patients in relation to administration of recombinant human erythropoietin and angiotensin-converting enzyme inhibitors. <i>Peritoneal Dialysis International</i> , 2002, 22, 625-8.	2.3	1
81	Urea Peritoneal Transfer Evaluated Using Plasma Water Urea Concentrations. <i>Peritoneal Dialysis International</i> , 1994, 14, 243-247.	2.3	3
82	An Indirect Estimation of Effective Peritoneal Capillary Blood Flow in Peritoneally Dialyzed Uremic Patients. <i>Peritoneal Dialysis International</i> , 1993, 13, 39-40.	2.3	19
83	Peritoneal Transfer During Maximal Hyperosmotic Ultrafiltration in the Rat. <i>ASAIO Journal</i> , 1993, 39, 66-70.	1.6	3
84	Ultrafiltration and effective peritoneal blood flow during peritoneal dialysis in the rat. <i>Kidney International</i> , 1991, 39, 608-617.	5.2	40